Search Results

5.Recombinant proteins and mosaic proteins for serodiagnosis of hepatitis A virus infection

Van Thu Nguyen

Journal of Preventive Medicine 2000;10(4):0-0

6.Clinical Study of Fulminant Hepatitis in Childhood.

Se Wook OH ; Chan Yung KIM

Journal of the Korean Pediatric Society 1990;33(7):923-931

7.Guidance for clinical evaluation of drugs used in the tretment of hepatitis.

Ju Seop KANG ; Noon Seoung PARK ; Tae Moo YOO ; Ji Sun YANG ; Dong Sup KIM ; Ju Il KIM ; Kwang Sup KIL

Korean Journal of Medicine 2002;63(2):225-231

8.A prospective cross-sectional study on the prevalence and factors associated with Seroprotection after primary series of Hepatitis B vaccination

Adrienne Michelle B. Lu ; Maria Estela R. Nolasco ; Marilou G. Tan

Pediatric Infectious Disease Society of the Philippines Journal 2018;19(1):3-13

Objectives: To determine the prevalence and factors associated with seroprotection among children 3 months to 18 years old with primary Hepatitis B vaccination series Methodology: This is a prospective cross-sectional study done among children 3 months to 18 years old with complete primary series of Hepatitis B vaccination. Demographic, social and clinical data were correlated with reactivity to antibody to Hepatitis B surface antigen (antiHBs) (>10 IU/L),total antibody to Hepatitis B core antigen (total anti-HBc) and Hepatitis B surface antigen (HBsAg) serologic tests. Results: Among 110 subjects from different age groups,52% had seroprotective anti-HBs levels, with the highest noted among infants (3 months-2 years) at 82%, followed by 41% from the childhood group (3-9 years) and 26% from adolescent group (10-18 years). Seventy-four percent of subjects with <5 years interval from vaccination were seroprotected, 26% in subjects after 5-10 years, and 38% at more than 10 years after vaccination with significant difference on multi-logistic regression (p value 0.000/0.020). None of the other factors including gender, geographic area, age at first dose, vaccination schedule, type and place of vaccination were significantly associated with seroprotection. Conclusion Fifty-two percent of patients among different age groups were seroprotected. Seroprotection was significantly associated with the interval year after vaccination demonstrated at < 50% 5 years and beyond post-vaccination.
Hepatitis